ISSN: 2376-0419
+44 1300 500008
Subramanian Poonguzhali and P S Rajinikanth
Taylor��?s University, Malaysia
Posters & Accepted Abstracts: J Pharma Care Health Sys
The present study is aimed to prepare and evaluate the supersaturated self nanoemulsifying drug delivery (S-SNEDDS) system of a poor water soluble drug dutasteride in order to achieve a better dissolution rate which would further help in enhancing oral bioavailability compared to the SNEDDS. The present research work describes SNEDDS and S-SNEDDS of dutasteride using Capryol PGMC, CremophorEL, PEG400 and HPMC as precipitation inhibitors. The pseudo-ternary phase diagrams with presence and absence of drug were plotted to check for the emulsification range and also to evaluate the effect of dutaseride on the emulsification behavior of the phases. The mixtures consisting of oil (Capryol PGMC) with surfactant (Cremophor EL), co-surfactant (PEG 400) in 2:3 ratios were found to be optimum formulations. HPMC 0.5 mg was added in the S-SNEDDS preparation along with the above mentioned oil, surfactants and co-surfactants. Prepared formulations were evaluated for its particle size distribution, nanoemulsifying properties and robustness to dilution, self-emulsification time, drug content and in vitro dissolution. The optimized formulations were further evaluated for heating cooling cycle, centrifugation studies, freeze thaw cycling, particle size distribution and zeta potential were carried out to confirm the stability of the formed S-SNEDDS formulations. The prepared S-SNEDDS formulation revealed some excellent physicochemical characteristics such as mean particle size of <100 nm and percentage of drug dissolved within 5 min, >90% in dissolution media of pH 1.2 and 6.8. The preliminary results from our study suggest that the dutasterideloaded self-nanoemulsifying formulation shown a significant improvement in terms of the drug dissolution as compared with raw drug. Thus, this greater dissolution of dutasteride from formulations could lead to higher absorption and higher oral bioavailability in clinical application.
Email: poongsss@gmail.com